Liminatus Pharma, Inc. Warrants
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more
Liminatus Pharma, Inc. Warrants (LIMNW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.365x
Based on the latest financial reports, Liminatus Pharma, Inc. Warrants (LIMNW) has a cash flow conversion efficiency ratio of 0.365x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-600.61K) by net assets ($-1.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Liminatus Pharma, Inc. Warrants - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Liminatus Pharma, Inc. Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gammon Pakistan Ltd
KAR:GAMON
|
N/A |
|
Eco Depot Inc
PINK:ECDP
|
-0.430x |
|
People’s Merchant Finance PLC
CM:PMBN0000
|
N/A |
|
Dandot Cement Company Ltd
KAR:DNCC
|
N/A |
|
Sassy Gold Corp.
OTCQB:SSYRD
|
-0.012x |
|
CENTRAL PETROLEUM (C9J.SG)
STU:C9J
|
N/A |
|
Caledonian Holdings PLC
LSE:CHP
|
0.000x |
|
TANFIELD GRP
BE:XS3A
|
N/A |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Warrants (2021–2024)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Warrants from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -7.58% |
| 2023-12-31 | $-15.79 Million | $-3.35 Million | 0.212x | +163.46% |
| 2022-12-31 | $-10.81 Million | $-869.00K | 0.080x | +1785.08% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |